Belinostat gets European orphan drug designation for the treatment of malignant thymomas
July 18, 2013 07:03 ET
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 19-13 / Copenhagen, July 18, 2013
On July 17, 2013, the European Commission granted Topotarget an orphan drug designation for belinostat...
Positive subtype data fra BELIEF-studiet præsenteret på 12th International Conference on Malignant Lymphoma
June 17, 2013 06:03 ET
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 18-13 / København, 17. juni 2013
Topotarget offentliggør, at positive subtype data på angioimmunoblastisk T-celle lymfekræft (AITL) fra BELIEFstudiet...
Positive subtype data from the BELIEF trial presented at the 12th International Conference on Malignant Lymphoma
June 17, 2013 06:03 ET
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 18-13 / Copenhagen, June 17, 2013
Topotarget announces that positive subtype data on angioimmunoblastic T-cell lymphoma (AITL) from the BELIEF trial...
Positive data fra BELIEF-studiet præsenteret på 2013 ASCO (American Society of Clinical Oncology) årsmødet
June 03, 2013 02:00 ET
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 17-13 / København, 3. juni 2013
Topotarget annoncerede i dag positive resultater fra BELIEF-studiet, et pivotalt, enkeltarms-studie af belinostat i...
Positive data from the BELIEF trial presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2013 02:00 ET
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement no. 17-13 / Copenhagen, June 3, 2013
Topotarget today announced positive results from the BELIEF trial, a pivotal, single-arm study of belinostat in...
Belinostat resuméer på ASCO 2013
May 16, 2013 02:31 ET
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 16-13 / København, 16. maj 2013
Topotarget offentliggør at kliniske belinostat resuméer den 15. maj 2013 kl. 18.00 EDT er blevet offentliggjort i...
Belinostat abstracts at ASCO 2013
May 16, 2013 02:31 ET
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement No. 16-13 / Copenhagen, May 16, 2013
Topotarget announces that abstracts on belinostat clinical data were released for ASCO 2013 on May 15, 2013 at 6.00...
Final data from BELIEF study for ASCO 2013 confirms objective response rate of 26%
May 16, 2013 02:07 ET
|
Topotarget
To NASDAQ OMX Copenhagen A/S
Announcement No. 15-13 / Copenhagen, May 16, 2013
Topotarget announces that an abstract containing positive final data from the registrational BELIEF study with...
Endelige data fra BELIEF-studiet til ASCO 2013 bekræfter objektiv responsrate på 26 %
May 16, 2013 02:07 ET
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Meddelelse nr. 15-13 / København, 16. maj 2013
Topotarget meddeler hermed, at der er frigivet et videnskabeligt resumé med positive endelige data fra...
Aktionærmøder i København og Århus
May 14, 2013 10:47 ET
|
Topotarget
Til NASDAQ OMX Copenhagen A/S
Investor Nyhed nr. 06-13/ København, 14. maj 2013
Topotarget inviterer hermed til aktionærmøde i København tirsdag den 11. juni 2013 og i Århus torsdag den 13. juni...